The Opportunity for Precision Cancer Therapeutics
The type of cancer and how it’s treated is not just about where in the body the cancer originated, but the specific molecular and genetic makeup of each patient’s tumor. Precision medicine offers one of the greatest opportunities to develop precision cancer therapeutics and tailor treatments to the unique characteristics of each patient.
A More Targeted Approach to Treatment
Because cancer is so complex, researchers and scientists have sought to understand the genetic causes of cancer and what they have learned is that cancer can arise from any number, or combination, of genetic malfunctions that ultimately results in out-of-control growth and spread of tumors. This has enabled clinicians to take a more targeted approach to treatment, with the availability of precision cancer therapeutics.
The Critical Role of Tumor Profiling
There are multiple targets that may need to be addressed and each patient’s cancer is different and this is where tumor profiling plays a key role. The concept of evaluating an individual patient’s tumor dynamics to determine what drug, or combination of drugs, may be most effective, is in essence, precision medicine.
The ability to look at the genetic makeup of a patient’s tumor has contributed significantly to advances in precision cancer therapeutics. Today, many patients have treatment options based on the particular markers, or gene mutations, in their tumors. More specific treatments may result in improved overall survival, increased progression-free survival and fewer toxicities or side effects.
Our Proprietary Precision Cancer Monitoring® (PCM) Technology
Our proprietary Precision Cancer Monitoring® (PCM) technology enables highly-sensitive measuring of circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.
We plan to leverage our expertise and experience with biomarkers and technology in cancer to develop PCM-075 for the treatment of acute myeloid leukemia (AML), creating synergy for both diagnostics and therapeutic products and improved outcomes for cancer patients.